ATMPS's blockchain platform the world's first solution for personalized medicines?
![](/46/pdcnewsitem/08/53/83/blockchain-3019120_1920.jpg)
New ‘blockchain ecosystem’ has potential to track, from vein-to-vein, advanced therapies.
ATMPS's Hataali blockchain platform has been successfully tested with University Hospitals Birmingham NHS Foundation Trust’s system interface.
Data interoperability was shown to be possible, rendering the Hataali platform as the world’s first blockchain solution for advanced therapeutic medicinal products (ATMP).
Hataali is a new pioneering blockchain-based cell orchestration platform that is interoperable with any other stakeholder interface and is designed to track advanced therapies from vein-to-vein.
University Hospitals Birmingham NHS Foundation Trust (UHB) hosts the Midlands and Wales Advanced Therapy Treatment Centre (MW-ATTC), which is a consortium of NHS, academic and industry partners.
The MW-ATTC — supported by Innovate UK — is one of three centres in the ATTC network across the UK working together to accelerate ATMP delivery in the NHS.
The informatics work, led by UHB within the MW-ATTC, proposes one NHS platform via which ATMP manufacturers could liaise with hospitals. The integration of cell orchestration platforms with UHB’s system will allow full and transparent visibility of samples and treatments.
“For the MW-ATTC project, we have been developing a prototype IT system that can record scheduling and ordering data for ATMP treatments. The system offers a number of integration points (APIs) to any cell orchestration platform such that the platform can communicate the relevant data to the prototype NHS IT system,” said Professor Philip Newsome, Director of MW-ATTC, University of Birmingham.
The MW-ATTC project, led by UHB, will form an effective example for the advanced therapy community tracking system to be rolled-out on a national scale.
“It’s a big moment for the ATMP space, as this is now the first network created anywhere in the world based on a blockchain technology. It’s been designed to provide the infrastructure for other stakeholders such as developers, third-party logistics and clinics to join on a secure, immutable and interoperable digital platform," commented, Raja Sharif, CEO of ATMPS Ltd.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance